Suppr超能文献

角膜移植术后患者内路房角成形术的疗效与安全性:3年结果

Efficacy and Safety of Ab-Interno Canaloplasty in Post-Keratoplasty Patients: 3-Year Results.

作者信息

Redden Liam D, Riaz Kamran M, Murphy David A, Ding Kai, Khaimi Mahmoud A

机构信息

Dean McGee Eye Institute, University of Oklahoma Health Sciences Center, Oklahoma City, OK, USA.

出版信息

Clin Ophthalmol. 2024 Nov 30;18:3567-3577. doi: 10.2147/OPTH.S487384. eCollection 2024.

Abstract

PURPOSE

To evaluate the effectiveness and safety of ab-interno canaloplasty (ABiC) for managing intraocular pressure (IOP) in patients following keratoplasty over a three-year period.

METHODS

This retrospective analysis focused on post-keratoplasty patients treated with ABiC with the iTrack microcatheter (Nova Eye Medical, Fremont, CA, USA) at a single institution. The study assessed the procedure's impact on IOP control, graft survival, and reliance on topical hypotensive medications, with additional observation for any postoperative complications. Surgical success criteria included the percentage of eyes with IOP ≤15 mmHg, IOP ≤18 mmHg, ≥20% IOP reduction, medication-free eyes, and eyes with concurrent IOP and medication reductions.

RESULTS

ABiC was performed successfully in a cohort of 16 post-keratoplasty (7 penetrating keratoplasty and 9 endothelial keratoplasty (EK)) eyes. Preoperative mean IOP of 25.8±7.2 mmHg was significantly reduced to 13.4±2.9 mmHg (p<0.001) at 1 year postoperatively and maintained at 13.1±3.9 mmHg (p=0.009) at 3 years postoperatively. The mean number of glaucoma medications was 3.5±1.7 at baseline, 2.8±1.3 at 1 year (p=0.107), and 2.5±1.2 at 3 years postoperatively (p=0.088). Eight eyes (66.7%) maintained IOP ≤ 15 mmHg, and 10 eyes (83.3%) maintained ≥ 20% IOP reduction at 3 years. The mean IOP and medication reductions from baseline at 3 years were -49.2% and -28.6%, respectively. Graft clarity was preserved in all patients except for one case of late graft failure that necessitated a repeat EK procedure. Post-ABiC complications included transient hyphema in two patients, neither of which led to long-term adverse outcomes.

CONCLUSION

ABiC appears to be an effective and safe surgical intervention for sustained IOP reduction in post-keratoplasty patients. Graft survival trends are encouraging, and there was a low incidence of complications over a three-year follow-up period.

摘要

目的

评估内路小梁成形术(ABiC)在三年期间对角膜移植术后患者眼压(IOP)管理的有效性和安全性。

方法

这项回顾性分析聚焦于在单一机构接受使用iTrack微导管(美国加利福尼亚州弗里蒙特市Nova Eye Medical公司)进行ABiC治疗的角膜移植术后患者。该研究评估了该手术对眼压控制、植片存活以及对局部降压药物依赖的影响,并对任何术后并发症进行了额外观察。手术成功标准包括眼压≤15 mmHg、眼压≤18 mmHg、眼压降低≥20%、无需药物治疗的眼以及眼压和药物均减少的眼的百分比。

结果

在一组16只角膜移植术后眼(7只穿透性角膜移植术和9只内皮角膜移植术(EK))中成功进行了ABiC。术前平均眼压为25.8±7.2 mmHg,术后1年显著降至13.4±2.9 mmHg(p<0.001),术后3年维持在13.1±3.9 mmHg(p=0.009)。青光眼药物的平均数量在基线时为3.5±1.7,术后1年为2.8±1.3(p=0.107),术后3年为2.5±1.2(p=0.088)。8只眼(66.7%)在3年时眼压维持≤15 mmHg,10只眼(83.3%)在3年时眼压降低≥20%。术后3年相对于基线的平均眼压和药物减少率分别为-49.2%和-28.6%。除1例晚期植片失败需要重复进行EK手术外,所有患者的植片清晰度均得以保留。ABiC术后并发症包括2例患者出现短暂性前房积血,均未导致长期不良后果。

结论

ABiC似乎是一种有效且安全的手术干预措施,可使角膜移植术后患者的眼压持续降低。植片存活趋势令人鼓舞,在三年随访期内并发症发生率较低。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2a0a/11616415/81b0a664b0ec/OPTH-18-3567-g0001.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验